Evidence map›Paper›PMID 33728947›Full record

ReviewPharmacogenomics2021

Pharmacogenomics of oxycodone: a narrative literature review.

Nelly N Umukoro, Blessed W Aruldhas, Ryan Rossos, Dhanashri Pawale, Janelle S Renschler, Senthilkumar Sadhasivam

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacogenomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Opioid Detection Using Smartphone-Based Eye-Scanning.Sensors (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Nelly N UmukoroDepartment of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, IN 46202, USA.ORCID 0000-0002-3736-0910
Blessed W AruldhasDepartment of Anesthesia, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-2082-6454
Ryan RossosDepartment of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, IN 46202, USA.
Dhanashri PawaleDepartment of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, IN 46202, USA.
Janelle S RenschlerDepartment of Anesthesia, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-4197-3808
Senthilkumar SadhasivamDepartment of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, IN 46202, USA.ORCID 0000-0002-3689-8313
Indiana University Health · USChristian Medical College, Vellore · INIndiana University School of Medicine

Funding

Effects of Opioid Use Disorder in Pregnancy on Long-Term Maternal and Child OutcomesR01HD096800 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SADHASIVAM, SENTHILKUMAR · 2018 to 2022
$3.1M
Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical PainR01HD089458 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI SADHASIVAM, SENTHILKUMAR · 2016 to 2020
$2.5M
Bedside prediction of opioid-induced respiratory depression in children with pupillometryR21HD094311 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI SADHASIVAM, SENTHILKUMAR · 2018 to 2019
$433k
NICHD NIH HHS R01 HD089458NICHD NIH HHS R01 HD096800NICHD NIH HHS R21 HD094311
6 · The paper itself

Abstract

Oxycodone is a semisynthetic μ- and κ-opioid receptor with agonist with a broad scope of use including postoperative analgesia as well as control of neuropathic and cancer pain. Advantages over other opioids include prolonged duration of action, greater potency than morphine and lack of histamine release or ceiling effect. Individual responses to oxycodone can vary due to genetic differences. This review article aims to summarize the oxycodone literature and provide context on its pharmacogenomics and pharmacokinetics. The evidence for clinical effect of genetic polymorphisms on oxycodone is conflicting. There is stronger evidence linking polymorphic genetic enzymes CYP2D6 and CYP3A with therapeutic outcomes. Further, research is needed to discern all of oxycodone's metabolites and their contribution to the overall analgesic effect.

Indexed as

PharmacogeneticsAnalgesics, OpioidCytochrome P-450 CYP2D6Cytochrome P-450 CYP3AHumansMorphineOxycodonePolymorphism, GeneticAnalgesics, OpioidCytochrome P-450 CYP2D6Cytochrome P-450 CYP3AMorphineOxycodoneABCB1analgesiaCYP2D6CYP3Acytochrome P450geneticopioidOPRM1oxycodonepharmacodynamicspharmacogenomicspharmacokineticspolymorphismvariant

Identifiers

PMID33728947
PMCPMC8050982
OpenAlexW3136772521

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.